Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel antitrypanosomal agents.

Dietmar Steverding1, Kevin M Tyler

  • 1School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 TJ7, UK. dsteverding@hotmail.com

Expert Opinion on Investigational Drugs
|July 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The history of giardiasis.

Parasitology research·2025
Same author

Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates.

ACS omega·2025
Same author

The history of entamoebiasis.

Parasitology·2025
Same author

Increased Trypanocidal Activity of the Salinomycin Derivative Ironomycin Is Due to ROS Production and Iron Uptake Impairment.

Molecules (Basel, Switzerland)·2024
Same author

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug.

Experimental parasitology·2024
Same author

100 years since the publication of the suramin formula.

Parasitology research·2023
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

New drug discovery is crucial for treating Chagas disease and sleeping sickness. Researchers are identifying novel compounds with selective activity against trypanosomes, addressing limitations of current therapies.

Area of Science:

  • Neglected tropical diseases
  • Parasitology
  • Medicinal chemistry

Background:

  • Human trypanosomiases, including Chagas disease and sleeping sickness, pose significant health burdens.
  • Current treatments rely on outdated drugs with severe side effects and emerging resistance.
  • There is an urgent need for novel, effective, and safer antitrypanosomal therapies.

Purpose of the Study:

  • To review recent advancements in the discovery of new antitrypanosomal drug candidates.
  • To highlight compounds demonstrating potent and selective activity against trypanosomes.
  • To inform the development of next-generation treatments for human trypanosomiases.

Main Methods:

  • Literature review of recent research on antitrypanosomal drug discovery.

Related Experiment Videos

  • Analysis of studies reporting novel compound identification and screening.
  • Focus on compounds exhibiting selective toxicity towards trypanosomes.

    • Main Results:

    • Several novel classes of compounds have shown promising antitrypanosomal activity.
    • Specific agents demonstrate selective toxicity, sparing host cells.
    • Emerging drug candidates offer potential alternatives to existing treatments.

    Conclusions:

    • Significant progress has been made in identifying novel antitrypanosomal lead compounds.
    • Selective antitrypanosomal agents represent a promising avenue for new drug development.
    • Continued research is vital to translate these findings into effective therapies for neglected tropical diseases.